# BA Venture Partners

> BA Venture Partners is a VC fund in Foster City backing Biotechnology and Software. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Foster City, United States
- Total investments: 8
- Last investment: Oct 2005
- Lead investor: 13%
- Last updated: Aug 2026

BA Venture Partners is a VC fund in Foster City focused on Biotechnology and Software. BA Venture Partners

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 38% |
| Software | 2 | 25% |
| Health Care | 2 | 25% |
| Therapeutics | 2 | 25% |
| Pharmaceutical | 2 | 25% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 38% |
| Series B | 2 | 25% |
| Series A | 1 | 13% |
| Funding Round | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AGEIA Technologies | AGEIA Technologies, Inc. develops hardware-accelerated physics for PC games. It offers PhysX, a physics engine and processor that bridges the gap between static virtual worlds and responsive unscripted physical reality. The company’s PhysX processor also provides hardcore gamers and gaming enthusiasts with simulations of collisions, explosions,complex jointed geometries, fabrics, dense smoke and liquids, multiple objects and particles, and other physical effects. It also offers a software development kit to simplify physics programming and gaming consoles. AGEIA Technologies was founded in 2002 and is based in Santa Clara, California with an additional office in Mountain View, California. As of February 10, 2008, AGEIA Technologies, Inc. operates as a subsidiary of NVIDIA Corporation. | $27.5M | Series C | Oct 03, 2005 |  |
| Somaxon Pharmaceuticals | Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketingproprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States. | $65M | Series C | Jun 06, 2005 |  |
| Arena Solutions | Arena Solutions helps innovative electronic high tech and medical device companies create products that change the world. Arena unifies product lifecycle (PLM) and quality management (QMS) processes, allowing every participant throughout the product realization process from design to manufacturing to work together. With Arena, teams accelerateproduct development and delivery to increase profits. For more information, visit ArenaSolutions.com. | $15M |  | Apr 05, 2005 |  |
| Prestwick Pharmaceuticals | Prestwick Pharmaceuticals develops and markets therapeutic pharmaceutical drugs for chronic central nervous systems diseases. The company offers products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea ailments. Prestwick Pharmaceuticals was founded in 2002 and is based in Washington, District of Columbia. | $37M | Series B | Dec 06, 2004 |  |
| Cellective Therapeutics | Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal responseto infections. | $27.5M | Series A | Sep 29, 2004 |  |
| Somaxon Pharmaceuticals | Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketingproprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States. | $23M | Series B | Jun 15, 2004 |  |
| Zone Labs | Zone Labs is a provider of endpoint security solutions.Zone Labs(R), one of the most trusted brands in Internet security, is a leading creator of endpoint security solutions protecting millions of PCs and the valuable, personally-identifiable information on those PCs, from hackers, spyware and data theft. The company's award-winning endpointsecurity product line is deployed in global enterprises, small businesses and consumers' homes, protecting them from Internet-borne threats. Zone Labs Integrity(TM) is an endpoint security management platform that protects corporate data and productivity. ZoneAlarm(R) Pro, ZoneAlarm Plus and ZoneAlarm are among the most popular and successful Internet security products available today while IMsecure(TM) Pro offers comprehensive security for instant messaging.Founded in 1997, Zone Labs is a private company headquartered in San Francisco, California, USA, with European headquarters in Frankfurt, Germany and offices in Japan and Singapore. | $25.2M | Series C | Jun 11, 2002 |  |
| Mblox | Founded in 1999, Mblox are the original SMS company. With over 100 direct carrier relationships and a global reputation for expertise in mobile messaging, they are trusted by more companies to carry their mission-critical traffic than any other service.Their cloud based mobile messaging platform processes 7 billion mobile messages a year onbehalf of more than 4,000 customers. They provide services to fit any size business, from the small start-up to the largest multinational organisation.Every customer has access to 24/7 email support as standard, provided by an in-house team of experts. In addition they offer a variety of support packages to meet your business needs. |  | Series A |  |  |

8 of 8 investments shown.

## Co-investors
- [CDIB BioScience Ventures](https://shizune.co/investors/profile/cdib-ventures) — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Montreux Equity Partners](https://shizune.co/investors/profile/montreaux-equity-partners) — VC Fund, 2 deals together
- [Scale Venture Partners](https://shizune.co/investors/profile/scale-venture-partners) — VC Fund, 2 deals together
- [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures) — VC Fund, 2 deals together
- Adelson Family Foundation — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does BA Venture Partners invest in?

BA Venture Partners invests primarily in Biotechnology, Software and Health Care startups, most often at Series C and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did BA Venture Partners last invest?

The most recent investment recorded for BA Venture Partners closed in Oct 2005. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co